# OncoSTING

Source: https://onco.cc/companies/oncosting/  
OnCo record `oncosting` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

OncoSTING is developing OS-151, a modified form of the BCG bladder treatment that also releases a strong immune-activating molecule, for bladder cancer. It is in laboratory testing.

## Summary

OncoSTING develops recombinant BCG immunotherapies engineered for sustained release of STING agonists. Its lead, OS-151, is a second-generation BCG that produces high levels of a STING agonist while keeping the activity of traditional BCG, aimed at non-muscle invasive bladder cancer and, as an intratumoral therapy, other solid tumours; the company reports it was more effective and better tolerated than traditional BCG in preclinical models. In fiscal year 2026 NCI awarded it USD 1,030,215 under SBIR award 1R44CA310037-01 for STING agonist-expressing BCG in bladder cancer.

## Fields

- Kind: Company
- Last checked: 2026-11-04
- Also known as: OncoSTING LLC; ONCOSTING LLC
- HQ: Baltimore, MD
- Type: biotech
- Website: https://www.oncosting.com/

## Notes

- Read on oncosting.com and NIH RePORTER on 4 November 2026.

## Sources

- Official website: https://www.oncosting.com/
- OncoSTING: technology: https://www.oncosting.com/technology
- NIH RePORTER: SBIR award 1R44CA310037-01: https://reporter.nih.gov/project-details/11312959

## Connected records

- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/)
- fronts: [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- technologies: [Intravesical therapy (BCG, chemotherapy, devices, gene and viral therapy)](https://onco.cc/technologies/bcg-and-intravesical-therapy/), [STING & innate immune agonists](https://onco.cc/technologies/sting-agonist/)
- drugs: [OS-151](https://onco.cc/drugs/os-151/)

---
JSON: https://onco.cc/api/v1/entities/oncosting.json